Schedule 13D ownership disclosure
Prelude Therapeutics, Inc.
Security class unavailable · CUSIP: 74065P101
Event date: 2020-09-25
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 33.9000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000947871-20-000772
- Form type
- SC 13D
- Filer
- ORBIMED ADVISORS LLC
- CIK
- CIK 1055951
- Filed
- Oct 05, 2020
- Reporting period
- Sep 25, 2020
- Description
- Schedule 13D beneficial ownership